Lemme GLP-1 Daily Review 2026: The Trial Behind the GLP-1 Claim Measured Weight and Found Nothing

The supplement facts panel is short, complete and honest about amounts. Serving size is 2 capsules, 30 servings per container.

The GLP-1 claim rests on Eriomin, a lemon flavonoid standardised to eriocitrin, made by Ingredients by Nature. Its pivotal trial is a genuine one — double-blind, randomised, placebo-controlled, published, and indexed in PubMed Central. Here is what that trial actually was. 103 prediabetic adults, average age 49, average BMI 34.1, randomised to 200 mg, 400 mg or 800 mg of Eriomin daily or placebo, for 12 weeks. The results were real and, on their own terms, good. Blood glucose fell. Insulin resistance improved. Inflammatory and oxidative-stress markers came down. GLP-1 rose by roughly 15% across all three doses (p < .001). The authors concluded the prediabetic condition was reversed in 24% of patients. That is a meaningful metabolic finding, and it is why Eriomin has a legitimate place in blood-sugar formulations. Now the part that matters for a product sold for weight. The trial measured body weight and BMI. Body weight changed by 0.2% or less. BMI changed by 0.9% or less. Neither was significant. Read that against the population: 103 people with an average BMI of 34, taking the ingredient for three months, with their GLP-1 confirmed to have risen 15% — and their weight did not move. This is not us finding an obscure limitation buried in a supplementary table. Weight and BMI were measured endpoints. The answer was no. So the mechanism claim is supported and the outcome claim is not, in the same study, from the same people. GLP-1 went up. Weight stayed where it was.

Lemme's product page carries a set of striking percentages: 69% felt less hungry, 70% felt decreased appetite, 55% decrease in snacking events. Earlier marketing also cited 65% reduced sugar cravings. Those numbers are not made up. They also are not about this product. They come from the trial behind Supresa, the saffron extract — a 2010 randomised, placebo-controlled study of 60 mildly overweight healthy women taking 176.5 mg/day for 8 weeks. The ingredient supplier, PLT Health Solutions, summarises it as producing significantly greater body-weight reduction, a 55% decrease in snacking and a 69% decrease in appetite. Lemme footnotes the study, which is more than many brands bother to do. Two things follow. First, 60 women over 8 weeks is a small, single, sponsor-relevant study, and the paper's own framing is that saffron's mechanism here is mood-mediated — feeling better, therefore snacking less — rather than direct appetite suppression. The weight difference against placebo in that literature is modest, on the order of about a kilogram. Second, and more importantly: a percentage from one ingredient's trial, printed on a page selling a three-ingredient product, reads to a normal shopper as a result of the product. Nobody scanning a landing page parses "69%" as "69%, in 60 women, from one of the three things in here, tested by itself, sixteen years ago." That is the gap this whole category lives in.

If you want the honest best case for this formula, it is Morosil — and it is better than we expected. The trial is a 6-month randomised, double-blind, placebo-controlled study of 400 mg/day of standardised Moro blood orange extract in overweight adults with BMI 25–33. The numbers:

Three ingredients. Three separate trials. Three separate populations — prediabetic adults with BMI 34, mildly overweight women, overweight adults with BMI 25–33. Three separate durations — 12 weeks, 8 weeks, 6 months. Zero trials of the three together, which is the thing you are actually buying. This is not a technicality, and it is the exact allegation at the centre of the litigation Lemme has faced. In Robins v. Lemme Inc. — filed in Los Angeles Superior Court on February 19, 2025 (No. 25STCV04635) and in the Southern District of New York on March 9, 2025 (No. 1:25-cv-01938) — the plaintiff challenged Lemme's marketing of GLP-1 Daily, including the claim that it boosts the body's GLP-1 production by up to 17%, and the positioning of the capsule as a cheaper alternative to Ozempic and Wegovy. The complaints' core argument is the one above: that while Lemme claimed clinical support for the *components*, it did not study the combination of those extracts in a single supplement — and that the component studies do not demonstrate the weight-loss effect being advertised. Lawyers following the case noted the specific legal hook: marketing that says "clinically studied" is treated as an *establishment claim*, meaning the advertiser is representing that a particular level of proof exists, and can be made to show it. Lemme called the suit frivolous. The federal case was voluntarily dismissed. And then, in July 2026, a fresh class action was filed in California over the rebranded Lemme Reset, under California's False Advertising Law, Unfair Competition Law and Consumer Legal Remedies Act — again alleging the product was sold as a natural alternative to prescription GLP-1 medication without adequate substantiation. We are not a court and we are not calling the outcome. What we can say is that the factual premise the complaints rest on — three ingredients, three studies, no study of the three together — is accurate, and you can verify it yourself in about twenty minutes.

Lemme GLP-1 Daily is now Lemme Reset™. The formula is unchanged. The product page URL is still /products/lemme-glp-1. Retail listings and third-party sellers still carry the old name, which is why searching for either lands you in the same place. Renaming a product is not misconduct. But compare the current page with what the litigation describes, and the direction of travel is clear:

$80 for 30 servings if you buy once. Subscription pricing runs $64/month, $180 for three months and $336 for six months, the last working out to $56 a month. So the honest arithmetic: at the subscription price you are paying roughly $64–$80 a month for 200 mg of a citrus flavonoid, 176.5 mg of saffron extract and 400 mg of red orange extract. Generic single-ingredient versions of all three exist for a fraction of that — the premium here is the branded extracts, the correct dosing, and the brand. On-site reviews sit at 4.3 out of 5 from 1,176 ratings, and the distribution is worth reading rather than the average: 778 five-star and 79 one-star. A brand's own review widget is a selection-biased instrument in both directions, and a large one-star cluster on a product like this usually reflects the gap between what buyers expected and what a supplement can do. Independent commentary has been consistently unimpressed. The registered dietitians, physicians and journalists who have covered this category — in NBC News, Harvard's public-health coverage, PBS NewsHour and diaTribe among others — land in the same place: OTC GLP-1 supplements are not remotely comparable to GLP-1 agonist medication, and the weight effects, where measurable at all, run to a few pounds.

It may be worth trying if: you are not a candidate for prescription GLP-1 therapy, you understand you are buying a modest metabolic nudge rather than a drug, and you specifically want branded extracts at verified clinical doses rather than the cheapest available powder. On that narrow brief, Lemme genuinely delivers what it says is in the bottle. It may be worth it if what you actually want is the glucose data. The strongest evidence attached to any of these three ingredients is Eriomin's effect on fasting glucose, insulin resistance and inflammation in prediabetes. If that is your situation, this is a defensible ingredient — bought for that reason, discussed with the clinician managing your glucose, and not expected to move the scale. Skip it if: you are buying it as an Ozempic alternative, which is the reason most people find it and the thing the evidence most clearly does not support; you want the combination itself to have been tested, because it has not been; or $64–$80 a month is money you would rather put toward protein, resistance training or an actual medical evaluation, all three of which have better evidence behind them for the outcome you want. And if you are in the position most readers of this page are in — overweight, frustrated, priced out of branded GLP-1s and looking for something that works — the honest answer is that the gap between this and prescription therapy is not a small one you can close with a better supplement. It is worth pricing out what supervised treatment actually costs before spending $960 a year on capsules. Our comparison of online GLP-1 programs covers what the legitimate options run.

Does Lemme GLP-1 Daily actually work? It depends entirely on what you mean by work. The trial behind its GLP-1 ingredient did raise GLP-1 by about 15% over 12 weeks and improved glucose control. That same trial measured body weight and found a change of 0.2%. The Morosil ingredient has separate 6-month data showing about 1.7 kg more weight loss than placebo. Nothing here approaches the effect of prescription GLP-1 medication. Is Lemme Reset the same as Lemme GLP-1 Daily? Yes. Same formula, renamed. The product page URL is still /products/lemme-glp-1. What is the Lemme GLP-1 lawsuit about? Robins v. Lemme Inc. was filed in Los Angeles Superior Court in February 2025 and the Southern District of New York in March 2025, alleging the weight-loss and "boost GLP-1 by up to 17%" claims were not substantiated and that the three extracts had never been studied in combination. The federal case was voluntarily dismissed. A new California class action over the rebranded Lemme Reset was filed in July 2026. Does it contain actual GLP-1? No. It contains no GLP-1, no synthetic GLP-1 and no GLP-1 receptor agonist. Lemme now says this explicitly on the product page. Are the ingredients at real clinical doses? Yes, and this is the product's strongest point. Eriomin 200 mg, Supresa 176.5 mg and Morosil 400 mg all match the doses used in their respective trials. Where do the 69% and 55% figures come from? From the Supresa saffron trial — 60 mildly overweight women, 8 weeks, one ingredient tested alone. Not from a study of Lemme Reset. Can I take it with Ozempic, Wegovy, Mounjaro or Zepbound? Ask your prescriber. There is no known dangerous interaction, but stacking appetite suppression on top of a GLP-1 agonist risks inadequate intake and muscle loss, which is already the main nutritional concern on these drugs. What are the side effects? The published trials reported no serious adverse effects. The plausible complaints are gastrointestinal — citrus extracts can cause heartburn or stomach discomfort, and saffron at higher doses has been associated with GI upset. Is $80 a month reasonable? For branded extracts at correct doses, it is a premium but not an absurd price. For the outcome most buyers are hoping for, it is $960 a year against evidence that does not support that outcome.